University of Georgia
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Tag: Trypanosoma cruzi

Rick Tarleton elected AAAS Fellow

Donna Huber on November 30, 2020

Photo credit: Andrew Tucker University of Georgia researcher Rick Tarleton has been elected as a 2020 American Association for the Advancement of Science (AAAS) Fellow by the AAAS Council “for distinguished contributions to the field of biological sciences, particularly for his research contributions and leadership to control Chagas Disease.” Tarleton is a Regents Professor in …

Outbreak News Today Interviews Rick Tarleton

Donna Huber on November 9, 2020

Recently, Dr. Rick Tarleton was interviewed by Outbreak News Today about his recently published study in Science Translational Medicine. [button size='large' style='' text='Listen Now' icon='' icon_color='BA0C2F' link='http://outbreaknewstoday.com/chagas-disease-treatment-research-with-rick-tarleton-phd-81114/' target='_self' color='' hover_color='' border_color='' hover_border_color='' background_color='' hover_background_color='' font_style='' font_weight='' text_align='' margin='']

Stronger treatments could cure Chagas disease

Donna Huber on October 30, 2020

3D (left) and single slice (right) light sheet microscopy imaging of the heart of a mouse infected with two strains (red and blue) of Trypanosoma cruzi. (Image credit: Fernando Sanchez-Valdez) Research shows stronger but less frequent drug doses could be key Researchers in the University of Georgia’s Center for Tropical and Emerging Global Diseases have found …

A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease

Donna Huber on October 28, 2020

A major contributor to treatment failure in Chagas disease, caused by infection with the protozoan parasite Trypanosoma cruzi, is that current treatment regimens do not address the drug insensitivity of transiently dormant T. cruzi amastigotes. Here, we demonstrated that use of a currently available drug in a modified treatment regimen of higher individual doses, given less frequently over …

Signaling pathways involved in environmental sensing in Trypanosoma cruzi

Donna Huber on October 9, 2020

Trypanosoma cruzi is a unicellular parasite and the etiologic agent of Chagas disease. The parasite has a digenetic life cycle alternating between mammalian and insect hosts, where it faces a variety of environmental conditions to which it must adapt in order to survive. The adaptation to these changes is mediated by signaling pathways that coordinate …

IP3 receptor-mediated Ca2+ release from acidocalcisomes regulates mitochondrial bioenergetics and prevents autophagy in Trypanosoma cruzi

Donna Huber on September 2, 2020

In contrast to animal cells, the inositol 1,4,5-trisphosphate receptor of Trypanosoma cruzi (TcIP3R) localizes to acidocalcisomes instead of the endoplasmic reticulum. Here, we present evidence that TcIP3R is a Ca2+ release channel gated by IP3 when expressed in DT40 cells knockout for all vertebrate IP3 receptors, and is required for Ca2+ uptake by T. cruzi mitochondria, regulating pyruvate dehydrogenase …

Cutting Edge: Augmenting Muscle MHC Expression Enhances Systemic Pathogen Control at the Expense of T Cell Exhaustion

Donna Huber on June 26, 2020

Myocytes express low levels of MHC class I (MHC I), perhaps influencing the ability of CD8+ T cells to efficiently detect and destroy pathogens that invade muscle. Trypanosoma cruzi infects many cell types but preferentially persists in muscle, and we asked if this tissue-dependent persistence was linked to MHC expression. Inducible enhancement of skeletal muscle MHC I in …

New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected With Trypanosoma cruzi: Clinical, Parasitological and Serological Assessment After Three Years of Follow-Up

Donna Huber on June 22, 2020

Introduction. In a pilot study, we showed that intermittent administration of benznidazole in chronic Chagas disease patients resulted in a low rate of treatment suspension and therapeutic failure, as assessed by qPCR at the end of treatment. Herein, a three-year post-treatment follow-up study of the same cohort of patients is presented. Methods. The treatment scheme consisted …

CRISPR/Cas9 Technology Applied to the Study of Proteins Involved in Calcium Signaling in Trypanosoma cruzi

Donna Huber on March 28, 2020

Chagas disease is a vector-borne tropical disease affecting millions of people worldwide, for which there is no vaccine or satisfactory treatment available. It is caused by the protozoan parasite Trypanosoma cruzi and considered endemic from North to South America. This parasite has unique metabolic and structural characteristics that make it an attractive organism for basic research. The …